全文获取类型
收费全文 | 7253篇 |
免费 | 649篇 |
国内免费 | 195篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 65篇 |
妇产科学 | 54篇 |
基础医学 | 355篇 |
口腔科学 | 361篇 |
临床医学 | 1182篇 |
内科学 | 685篇 |
皮肤病学 | 123篇 |
神经病学 | 242篇 |
特种医学 | 663篇 |
外科学 | 374篇 |
综合类 | 938篇 |
预防医学 | 506篇 |
眼科学 | 91篇 |
药学 | 1806篇 |
2篇 | |
中国医学 | 221篇 |
肿瘤学 | 409篇 |
出版年
2024年 | 4篇 |
2023年 | 71篇 |
2022年 | 92篇 |
2021年 | 210篇 |
2020年 | 200篇 |
2019年 | 177篇 |
2018年 | 174篇 |
2017年 | 230篇 |
2016年 | 222篇 |
2015年 | 274篇 |
2014年 | 492篇 |
2013年 | 571篇 |
2012年 | 482篇 |
2011年 | 432篇 |
2010年 | 343篇 |
2009年 | 345篇 |
2008年 | 343篇 |
2007年 | 396篇 |
2006年 | 402篇 |
2005年 | 262篇 |
2004年 | 234篇 |
2003年 | 252篇 |
2002年 | 219篇 |
2001年 | 173篇 |
2000年 | 124篇 |
1999年 | 154篇 |
1998年 | 142篇 |
1997年 | 152篇 |
1996年 | 97篇 |
1995年 | 84篇 |
1994年 | 96篇 |
1993年 | 74篇 |
1992年 | 79篇 |
1991年 | 65篇 |
1990年 | 56篇 |
1989年 | 60篇 |
1988年 | 50篇 |
1987年 | 44篇 |
1986年 | 39篇 |
1985年 | 46篇 |
1984年 | 23篇 |
1983年 | 13篇 |
1982年 | 26篇 |
1981年 | 15篇 |
1980年 | 12篇 |
1979年 | 8篇 |
1978年 | 12篇 |
1977年 | 12篇 |
1976年 | 8篇 |
1973年 | 3篇 |
排序方式: 共有8097条查询结果,搜索用时 15 毫秒
1.
2.
《Clinical Lymphoma, Myeloma & Leukemia》2022,22(9):e853-e866
Introduction/BackgroundTherapy with infused or injected hypomethylating agents (HMAs) may lead to higher treatment administration burden (ie, local reaction, visit frequency and duration) vs. oral HMAs. ObjectivesTo reveal preferences of US and Canadian patients with myelodysplastic syndromes (MDS) for HMAs’ benefits, risks, and administration burden through an online discrete-choice experiment (DCE).Materials and MethodsChoice of DCE attributes and survey development were informed by literature review and interviews with clinicians, MDS patients, and caregivers serving as patient proxies, and patient advocacy groups (PAGs) representatives, including from AAMAC, AAMDS, and MDSF. DCE choice tasks were analyzed using random parameter logit models. Survey patients were recruited by the PAGs via their networks. To understand key preference drivers and how much patients were willing to trade between attributes, we calculated each attribute's relative attribute importance (RAI) and marginal rates of substitution.ResultsOne hundred eighty-four respondents (including 158 patients; mean age, 67.2 years; male, 50.5%; White, 50.5%; US residents, 88%) completed the survey. MDS risk was low (34.8%), high (30.9%), or unknown (34.2%). RAI (in decreasing order) was as follows: risk of AML (40%), fatigue level (33%), number of visits (12%), mode of administration (6%), visit duration (5%), and administration frequency (4%). Assuming the same risk of AML transformation or level of fatigue, most respondents (76.6%) were predicted to switch to an oral pill if it were available to them.ConclusionGiven equivalent effectiveness across HMAs, patients’ preferences for HMA administration method should be considered in treatment decision-making to minimize burden and facilitate adherence. 相似文献
3.
4.
5.
Ramya C. Mosarla Muthiah Vaduganathan Arman Qamar Javid Moslehi Gregory Piazza Robert P. Giugliano 《Journal of the American College of Cardiology》2019,73(11):1336-1349
Patients with active cancer are at an increased risk of arterial and venous thromboembolism (VTE) and bleeding events. Historically, in patients with cancer, low molecular weight heparins have been preferred for treatment of VTE, whereas warfarin has been the standard anticoagulant for stroke prevention in patients with atrial fibrillation (AF). More recently, direct oral anticoagulants (DOACs) have been demonstrated to reduce the risk of venous and arterial thromboembolism in large randomized clinical trials of patients with VTE and AF, respectively, thus providing an attractive oral dosing option that does not require routine laboratory monitoring. In this review, we summarize available clinical trial data and guideline recommendations, and outline a practical approach to anticoagulation management of VTE and AF in cancer. 相似文献
6.
7.
The developmental path for venetoclax in acute myeloid leukemia (AML) has been rapid and stands in stark contrast to the incremental progress that has characterized the field in previous decades. For perspective, on December 31, 2013, the first AML patient was enrolled into a study using venetoclax; 59 months later, on November 21, 2018, venetoclax received accelerated approval by the FDA for use in AML. In June 2020, Dr. DiNardo presented the results of the required confirmatory study at the European Hematology Association meeting, showing that venetoclax with azacitidine resulted in a superior response rate and overall survival compared to azacitidine alone for older, newly diagnosed AML patients. This swift progress has provided a welcome and potent new therapy for patients with AML; with it come questions about how its role can be expanded, and how its use can be optimized. 相似文献
8.
9.
Kamil Kuca Kamil Musilek Daniel Jun Eugenie Nepovimova Ondrej Soukup Jan Korabecny 《Toxin reviews》2020,39(2):157-166
AbstractOxime K074 was formerly considered to be a lead structure for design of novel oximes for reactivation of tabun-inhibited acetylcholinesterase (AChE). In this study, we are summarizing its reactivation activity in case of other nerve agents (sarin, cyclosarin, VX and Russian VX) and pesticides (chlorpyrifos, methylchlorpyrifos and DDVP). For this purpose, standard in vitro method using rat brain homogenate was used. As resulted, oxime K074 was able to reactivate brain ChE (cholinesterases) inhibited by all used nerve agents and pesticides excluding cyclosarin-inhibited ChE. Only slight modification in structure of sarin (isopropyl moiety) and cyclosarin (cyclohexyl moiety) caused extraordinary differences in the reactivation of acetylcholinesterase inhibited by these nerve agents. Obtained molecular docking results suggest that the oxime K074 interacts very well with the inhibitors addressed in this work, and the data obtained by the QM/MM approach showed a good correlation with our experimental results of reactivation rate (%) by the oxime K074. 相似文献
10.